Pilihan Pengobatan Artritis Rematoid
DOI:
https://doi.org/10.55175/cdk.v47i4.362Kata Kunci:
Antibodi monoklonal, artritis rematoid, DMARDAbstrak
Artritis rematoid (rheumatoid arthritis, RA) adalah salah satu penyakit autoimun yang prevalensinya tinggi, di Indonesia, yaitu diperkirakan 0,3%. Pengobatan RA dapat menjadi tantangan mengingat derajat gejala bisa sangat berbeda antar pasien, serta respons terhadap pengobatan juga tidak sama. Selain itu, juga berisiko efek samping. Artikel ini akan membahas pilihan-pilihan pengobatan RA.
Rheumatoid arthritis is an autoimmune disease with a high prevalence, the estimated prevalence in Indonesia is 0.3%. Treatment of rheumatoid arthritis can be challenging due to the variability of symptoms and severity, difference of response to treatment; in addition to side effects risks. This literature review will discuss some rheumatoid arthritis treatment options.
Unduhan
Referensi
Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis: ACR RA treatment recommendations. Arthritis Rheumatol. 2016;68(1):1–26.
Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014. Rheumatol Int. 2017;37(9):1551–7.
Abhishek A, Doherty M, Kuo CF, Mallen CD, Zhang W, Grainge MJ. Rheumatoid arthritis is getting less frequent-results of a nationwide population-based cohort study. Rheumatol Oxf Engl. 2017 01;56(5):736–44.
Yamanaka H, Sugiyama N, Inoue E, Taniguchi A, Momohara S. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Mod Rheumatol. 2014;24(1):33–40.
Perhimpunan Reumatologi Indonesia. [Internet]. [cited 2019 Sep 20]. Available from: https://reumatologi.or.id/reurek/ira
Rheumatoid arthritis: Practice essentials, background, pathophysiology [Internet]. [cited 2019 Oct 7]. Available from: https://emedicine.medscape.com/article/331715-overview
Felson D. Defining remission in rheumatoid arthritis. Ann Rheum Dis. 2012;71(0 2):i86–8.
Disease Activity & Functional Status Assessments [Internet]. [cited 2019 Oct 7]. Available from: https://www.rheumatology.org/Practice-Quality/Clinical-Support/Quality-Measurement/Disease-Activity-Functional-Status-Assessments
ACR score: What does an ACR score measure? RheumatoidArthritis.org [Internet]. [cited 2019 Oct 7]. Available from: https://www.rheumatoidarthritis.org/treatment/acr-score/
Gaujoux-Viala C, Smolen JS, Landewé R, Dougados M, Kvien TK, Mola EM, et al. Current evidence for the management of rheumatoid arthritis with synthetic diseasemodifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69(6):1004–9.
Londono J, Santos AM, Santos PI, Cubidez MF, Guzman C, Valle-Oñate R. Therapeutic efficacy and safety of methotrexate + leflunomide in Colombian patients with active rheumatoid arthritis refractory to conventional treatment. Rev Bras Reumatol. 2012;52(6):837–45.
Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe DJA, Bombardier C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. Cochrane Database Syst Rev. 2016;(8):CD010227.
van de Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, van Riel PLCM, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63(5):508–16.
Fleischmann R, Tongbram V, van Vollenhoven R, Tang DH, Chung J, Collier D, et al. Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor–methotrexate combination therapy versus triple therapy in rheumatoid arthritis. RMD Open [Internet]. 2017 Jan 3 [cited 2019 Oct 7];3(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237767/
Orencia (Abatacept): Side effects, interactions, warning, dosage & uses [Internet]. RxList. [cited 2019 Oct 7]. Available from: https://www.rxlist.com/orencia-drug.htm
Ma K, Li L, Liu C, Zhou L, Zhou X. Efficacy and safety of various anti-rheumatic treatments for patients with rheumatoid arthritis: A network meta-analysis. Arch Med Sci AMS. 2019;15(1):33–54.
González-Vacarezza N, Alemán A, González G, Pérez A. Rituximab and tocilizumab for the treatment of rheumatoid arthritis. Int J Technol Assess Health Care. 2014;30(3):282–8.
Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatol. 2019;58(Suppl._1):17–26.
McInnes IB, Byers NL, Higgs RE, Lee J, Macias WL, Na S, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183.
The role of the JAK/STAT signal pathway in rheumatoid arthritis [Internet]. [cited 2019 Oct 7]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009092/
Bergrath E, Gerber RA, Gruben D, Lukic T, Makin C, Wallenstein G. Tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients who have had an inadequate response to nonbiologic DMARDs: Systematic literature review and network meta-analysis. Int J Rheumatol. 2017;2017:8417249.
Wu ZP, Zhang P, Bai JZ, Liang Y, He JS, Wang JC. Efficacy and safety of baricitinib for active rheumatoid arthritis in patients with an inadequate response to conventional synthetic or biological disease-modifying anti-rheumatic drugs: A meta-analysis of randomized controlled trials. Exp Ther Med. 2018;16(3):2449–59.
Song GG, Choi SJ, Lee YH. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis. 2019;22(8):1563–71.
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events .PubMed - NCBI [Internet]. [cited 2019 Oct 7]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25561362
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2020 Cermin Dunia Kedokteran
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
